Core Insights - Nutex Health Inc. is preparing for its quarterly earnings announcement on September 18, 2025, with an expected EPS of -$5.43 and projected revenue of approximately $210.89 million [1][6] Financial Performance - The company is currently facing a class-action lawsuit alleging deceptive billing practices, which may impact its financial outlook [2][6] - Despite the legal challenges, Nutex's price-to-sales ratio is around 0.80, indicating it may be undervalued [3][6] - The enterprise value to sales ratio is approximately 1.21, and the enterprise value to operating cash flow ratio is about 10.64, providing insights into the company's valuation and cash flow generation capabilities [4] - Nutex's debt-to-equity ratio is reported at 1.73, suggesting a higher level of debt relative to equity, while the current ratio is approximately 2.27, indicating a strong capacity to cover short-term liabilities [5]